Mirror Worlds Technologies, LLC v. Meta Platforms, Inc., Appeal Nos. 2022-1600, -1709 (Fed. Cir. Dec. 4, 2024)
In this appeal from the United States District Court for the Southern District of New York, the Federal...more
12/10/2024
/ Appeals ,
Cross-Appeals ,
Doctrine of Equivalents ,
En Banc Review ,
Generic Drugs ,
Inter Partes Review (IPR) Proceeding ,
Noninfringement ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Industry ,
Summary Judgment ,
Technology
C.R. Bard Inc. v. AngioDynamics, Inc., Appeal No. 2019-1756, -1934 (Fed. Cir. Nov. 10, 2020) -
Our Case of the Week is one of two cases decided this week in which the Federal Circuit finds that a district court jumped the...more
11/17/2020
/ Appeals ,
Appellate Courts ,
Claim Construction ,
Discovery ,
Dismissals ,
Equitable Estoppel ,
Genuine Issue of Material Fact ,
Inter Partes Review (IPR) Proceeding ,
Inventors ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Petition for Writ of Certiorari ,
Pharmaceutical Patents ,
Summary Judgment
PATENT CASE OF THE WEEK -
Nalpropion Pharmaceuticals, Inc. v. Actavis Laboratories, FL, Inc., Appeal No. 2018-1221 (Fed. Cir. Aug. 15, 2019) -
This week’s Case of the Week focuses on issues relating to written...more
8/20/2019
/ Abbreviated New Drug Application (ANDA) ,
Claim Construction ,
Claim Limitations ,
Hatch-Waxman ,
Motion to Amend ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Section 101 ,
Written Descriptions
PATENT CASE OF THE WEEK -
Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc., Appeal Nos. 2017-2078, -2134 (Fed. Cir. Sept. 10, 2018)
The Federal Circuit affirmed the district court’s ruling following a bench trial,...more
9/18/2018
/ Bench Trial ,
De Novo Standard of Review ,
Inter Partes Review (IPR) Proceeding ,
International Trade Commission (ITC) ,
Nonobvious ,
Obviousness ,
Patent Applications ,
Patent Invalidity ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
Preponderance of the Evidence ,
Printed Publications ,
Prior Art
Praxair Distribution, Inc. v. Mallinckrodt Hospital Products IP Ltd., Appeal Nos. 2016-2616, -2656 (Fed. Cir. May 16, 2018) -
In an appeal from a inter partes review, the Federal Circuit reviewed a PTAB obviousness...more
5/22/2018
/ Burden of Proof ,
Claim Construction ,
Claim Limitations ,
Inter Partes Review (IPR) Proceeding ,
Obviousness ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Personal Jurisdiction ,
Pharmaceutical Patents ,
Prior Art ,
Section 101 ,
Venue ,
Writ of Mandamus
PATENT CASE OF THE WEEK -
SimpleAir, Inc. v. Google LLC, Appeal No. 2016-2738 (Fed. Cir. 2018) -
In SimpleAir, Inc. v Google LLC, the Federal Circuit vacated a district court’s motion to dismiss pursuant to Rule...more
3/20/2018
/ Appeals ,
Claim Construction ,
Claim Preclusion ,
Collateral Estoppel ,
Double Patent ,
Federal Rule 12(b)(6) ,
Inter Partes Review (IPR) Proceeding ,
Kessler Doctrine ,
Motion to Dismiss ,
Noninfringement ,
Obviousness ,
Parent Patents ,
Patent Applications ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Prior Art ,
Reversal ,
Terminal Disclaimer ,
USPTO ,
Written Descriptions
In Nidec v. Zhongshan, the entire panel affirms a determination of obviousness but two judges question whether § 315(c) of the AIA was improperly used to permit joinder as to a second Zhongshan petition filed after the...more
8/28/2017
/ Admissible Evidence ,
Appeals ,
Burden of Proof ,
Burden-Shifting ,
Inter Partes Review (IPR) Proceeding ,
Joinder ,
Limitation Periods ,
Nonobvious ,
Obviousness ,
Patents ,
Remand ,
USPTO ,
Vacated